JSPR

Insider Trades

Name	Value	Action	Price	Current Price
Martell RonDirector, Officer: President And CEO $120k41k shares BuySep 22, 2025 $2.92 --
Shizuru Judith AnneDirector $120k41k shares BuySep 22, 2025 $2.92 --
Wiggans Thomas GDirector $120k41k shares BuySep 22, 2025 $2.92 --
Martell RonDirector, Officer: President And CEO $100k41k shares BuySep 22, 2025 $2.43 --
Shizuru Judith AnneDirector $100k41k shares BuySep 22, 2025 $2.43 --
Wiggans Thomas GDirector $100k41k shares BuySep 22, 2025 $2.43 --

News

zacks.comBears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Nowzacks.comJun 3

globenewswire.comJasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Valueglobenewswire.comJun 1

globenewswire.comJasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updateglobenewswire.comMay 14

globenewswire.comJasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Updateglobenewswire.comMar 30

247wallst.comHere Are Monday’s Top Wall Street Analyst Research Calls: APA Corporation, Cheniere Energy, Crown Castle, Hut 8, MongoDB, Red Rock Resorts, Super Micro Computer, Terawulf, and More247wallst.comMar 23

Trade JSPR

About Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for hematopoietic stem cell transplantation and gene therapies. Its core mission is to develop and commercialize conditioning agents and advanced stem cell engineering methods. These advancements aim to expand the utility of stem cell transplantation and ex vivo gene therapy, a process involving genetic modification of cells outside the body before their transplantation. JSP191 stands as the company's leading investigational product, currently in clinical development. This conditioning antibody functions by ablating hematopoietic stem cells from patients' bone marrow as a prerequisite for allogeneic stem cell or stem cell gene therapy. Additionally, Jasper is creating engineered hematopoietic stem cell product candidates intended to address significant limitations inherent in both allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.

CEO: Jeetinder Singh Mahal
IPO Date: Jan 10, 2020

Market Data

Open: $0.4659
High: $0.4769
Low: $0.4414
Volume: 232.5K
Avg Volume: 508.6K
52W High: $7.19
52W Low: $0.42

Valuation

Market Cap: $7.4M
Enterprise Value: $-6.0M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-77M
Revenue: $0
Net Income: $-76M
Cash: $29M
Debt: $1.2M

Events

EarningsAug 12

EPS est. -0.38